|
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study |
Jan 2024 |
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
|
One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab |
Dec 2020 |
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study |
Oct 2020 |
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome |
Apr 2023 |
Blood Cancer |
Myelodysplastic Syndromes (MDS) |
|
Novel therapeutic choices in immune aplastic anemia |
Sep 2020 |
F1000Research |
Aplastic Anemia |
|
Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria |
Jul 2023 |
Clinical and Experimental Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment |
May 2023 |
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
|
Newly revised 2023 MDS response criteria |
Apr 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
New Approaches for Anemia in MDS |
Sep 2020 |
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes |
Jun 2023 |
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
